Sign In
Buy AKTX
$14.99
+0.355 (+2.43%)
At Close: Jun 03, 2026
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala
09:05am, Tuesday, 22'nd Apr 2025
Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari The
Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer
08:35am, Thursday, 20'th Mar 2025
Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have to
BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs)
Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
09:00am, Wednesday, 19'th Feb 2025
On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing next-generation precision bi-
Akari Therapeutics Joins Webull Corporate Connect Service Platform
08:00am, Monday, 03'rd Feb 2025
Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Thera
Akari Therapeutics Announces Key Leadership Appointments
08:51am, Wednesday, 18'th Dec 2024
Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKT
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer
09:05am, Monday, 16'th Dec 2024
BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16,
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
04:15pm, Thursday, 14'th Nov 2024
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger
08:00am, Friday, 08'th Nov 2024
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases,
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers and Imminent Votes on November 7, 2024, of AKTX and PKBO
06:45pm, Friday, 11'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Se
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
04:15pm, Monday, 19'th Aug 2024
Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic atrophy Pre-IND meeting with FDA completed with pos
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights
08:00am, Thursday, 16'th May 2024
Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
08:01am, Wednesday, 01'st May 2024
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announ
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
08:00am, Wednesday, 01'st May 2024
BOSTON and PLEASANTON, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX, “Akari”) and Peak Bio Inc. (OTC: PKBO, “Peak”) today announced completion of a joint port
